109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
Antisense oligonucleotides for the treatment of Stargardt disease
#1502METHODS FOR TREATING CANCERS USING ANTISENSE
#1503TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1504OLIGOMERS
#1505TAU-TARGETING OLIGONUCLEOTIDE GAPMERS
#1506Antisense oligonucleotide and double stranded RNAS for control of hemipteran and lepidopteran pests
#1507Oversubscription scheduling
#1508Compositions for modulating Ataxin 2 expression
#1509Linkage modified oligomeric compounds and uses thereof
#1510INTRACELLULAR TARGETING OF MOLECULES
#1511ANTISENSE OLIGONUCLEOTIDES FOR IMMUNOTHERAPY
#1512COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#1513Treatment and diagnosis of inflammatory disorders
#1514Oligonucleotides for modulating Tau expression
#1515Antisense Oligonucleotides Targeting ATXN3
#1516ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
#1517Modulation of prekallikrein (PKK) expression
#1518RNAI MOLECULE
#1519IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#1520Nucleic acid compound and oligonucleotide
#1521Ventricular arrhythmias and related methods
#1522Methods for reducing Ataxin-2 expression
#1523ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
#1524NOVEL RNA TRANSCRIPT
#1525Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1526NUCLEIC ACID COMPLEX FOR MODULATING IHH EXPRESSION
#1527NRL EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE
#1528ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#1529ANTISENSE NUCLEIC ACIDS
#1530POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#1531OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1532OLIGONUCLEOTIDE-POLYMER MIKTOARM CONJUGATES AND METHODS OF USE
#1533ANTISENSE NUCLEIC ACID TARGETING PCSK9
#1534NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDS
#1535ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#1536Compounds and methods for modulating angiotensinogen expression
#1537Therapeutic targets for facioscapulohumeral muscular dystrophy
#1538Oligonucleotides for inducing paternal UBE3A expression
#1539FRAGILE X MENTAL RETARDATION PROTEIN INTERFERING OLIGONUCLEOTIDES AND METHODS OF USING SAME
#1540TARGETS AND METHODS FOR TREATING EPSTEIN-BARR VIRUS MEDIATED NEURODEGENERATION
#1541OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1542CTLA-4 aptamer conjugates
#1543Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1544TAU ANTISENSE OLIGOMERS AND USES THEREOF
#1545INHIBITION OF LET7I AS A MEANS TO ENHANCE THE PROTECTIVE EFFECT OF PROGESTERONE AGAINST STROKE
#1546Antisense antibacterial compounds and methods
#1547OPTIMAL PS MODIFICATION PATTERN FOR HETERONUCLEIC ACIDS
#1548Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs
#1549NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1
#1550COMPOSITIONS AND METHODS FOR ALLEVIATING PAIN
#1551TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING
#1552Methods for Treatment of Alport Syndrome
#1553METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1554Functionally-Modified Oligonucleotides And Subunits Thereof
#1555METHODS AND COMPOSITIONS FOR MODULATING SPLICING AND TRANSLATION
#1556OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
#1557ANTISENSE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING
#1558METHODS AND MATERIALS FOR ACTIVATING AN INTERNAL RIBOSOME ENTRY SITE IN EXON 5 OF THE DMD GENE
#1559NUCLEIC ACID CONJUGATE
#1560ANTI-ARRHYTHMICITY AGENTS
#1561TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS
#1562ANTISENSE OLIGOMERS FOR CONTROLLING CANDIDA ALBICANS INFECTIONS
#1563METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1564METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1565METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1566METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1567Targeted control of pests and pathogens by plant delivery of 2′F-ANA-oligonucleotides
#1568COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#1569FORMULATION
#1570MYOSTATIN SIGNAL INHIBITOR
#1571NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL
#1572ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#1573VARIANTS OF ERYTHROFERRONE AND THEIR USE
#1574ANTISENSE OLIGOMERS AND USES THEREOF
#1575Trans-splicing ribozyme targeting rhodopsin transcript and uses thereof
#1576METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1577COMPOUNDS AND METHODS FOR REDUCING PMP22 EXPRESSION
#1578Modulation of GYS1 expression
#1579CANCER-SPECIFIC MOLECULES AND METHODS OF USE THEREOF
#1580Therapeutic compositions for treating pain via multiple targets
#1581PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES
#1582PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS
#1583METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD)
#1584Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1)
#1585Antiviral agents
#1586ANTIBACTERIAL ANTISENSE AGENTS
#1587SPLICE MODULATING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1588NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE
#1589Methods and compositions for editing RNAs
#1590OLIGONUCLEOTIDE
#1591ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER`S CONGENITAL AMAUROSIS
#1592MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#1593NEOANTIGENS CREATED BY ABERRANT-INDUCED SPLICING AND USES THEREOF IN ENHANCING IMMUNOTHERAPY
#1594COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
#1595ANTISENSE-INDUCED EXON EXCLUSION IN MYOSTATIN
#1596Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19
#1597HNF4a saRNA compositions and methods of use
#1598SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES
#1599CELL PENETRATING MOLECULE
#1600Bicyclic nucleosides and oligomers prepared therefrom
#1601Compositions and methods for treating spinal muscular atrophy
#1602ANTISENSE OLIGOMERS FOR TREATMENT OF AUTOSOMAL DOMINANT MENTAL RETARDATION-5 AND DRAVET SYNDROME
#1603RNAi agents for Hepatitis B virus infection
#1604METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1605ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY
#1606ANTISENSE OLIGONUCLEOIDES OF GLUTATHIONE S-TRANSFERASES FOR CANCER TREATMENT
#1607COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS
#1608METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS
#1609U1 snRNP Regulates Gene Expression and Modulates Oncogenicity
#1610NOVEL PHOSPHORAMIDITES
#1611COMPOUNDS AND METHODS FOR MODULATION OF SMN2
#1612METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#1613Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#1614Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#1615COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
#1616MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#1617COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
#1618COMPOUNDS AND METHODS FOR MODULATING SMN2
#1619COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERS
#1620Compounds and methods for modulating PLP1
#1621PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
#1622EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1623Antisense compounds targeting genes associated with cystic fibrosis
#1624Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1625Antisense nucleic acids
#1626Modulating the cellular stress response
#1627dsRNA Directed to Coronavirus Proteins
#1628Treatment of staphylococcal disorders
#1629RNA nanoparticles and method of use thereof
#1630COMBINATION THERAPY
#1631Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
#1632Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
#1633ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#1634CONJUGATED OLIGONUCLEOTIDES FOR TISSUE SPECIFIC DELIVERY
#1635Compositions and their uses directed to huntingtin
#1636ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9
#1637NEOANTIGEN COMPOSITIONS; AND METHODS OF PREPARATION AND USE THEREOF
#1638Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
#1639NEUROFILAMENT PROTEIN FOR GUIDING THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS
#1640POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#1641Oligonucleotides targeting RNA binding protein sites
#1642METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY
#1643COMPOSITIONS AND METHODS FOR NON-ANTIBIOTIC TREATING OF BACTERIAL INFECTIONS BY BLOCKING OR DISRUPTING BACTERIAL GENES INVOLVED IN VIRULENCE OR VIABILITY
#1644Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
#1645ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
#1646Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1647INDUCIBLE EXPRESSION OF GENES IN ALGAE
#1648Antisense oligomers targeting PCSK9
#1649OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
#1650BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
#1651METHODS OF MODULATING RNA
#1652Saponin Conjugates
#1653EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#1654METHODS OF CANCER TREATMENT
#1655OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES
#1656Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1657RNA AND DNA BASE EDITING VIA ENGINEERED ADAR RECRUITMENT
#1658Intron fragments
#1659ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
#1660COMPOSITIONS AND METHODS FOR MODULATING TRANSCRIPTIONAL ACTIVITY OF AMPLIFIED ONCOGENES CONTAINED ON EXTRACHROMOSOMAL DNA
#1661POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF
#1662METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
#1663AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1664Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease
#1665OLIGONUCLEOTIDE-MEDIATED SENSE CODON REASSIGNMENT
#1666Methods of Treating Influenza A Virus Infections
#1667Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein
#1668Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
#1669METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE
#1670Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#1671ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1672Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1673ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL
#1674POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
#1675MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
#1676Antisense Compounds Targeting Genes Associated with Cystic Fibrosis
#1677Splice-switching oligonucleotides and methods of use
#1678Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
#1679Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
#1680Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#1681SYNTHETIC OLIGONUCLEOTIDES HAVING REGIONS OF BLOCK AND CLUSTER MODIFICATIONS
#1682METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A)
#1683COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE
#1684COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#1685Monocarboxylate transporter (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
#1686Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides
#1687Compositions and methods for detection of SMN protein in a subject and treatment of a subject
#1688Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1689Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1690Modulators and modulation of the receptor for advanced glycation end-products RNA
#1691Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1692Oligonucleotide agonists targeting progranulin
#1693MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
#1694Dosages and methods for delivering lipid formulated nucleic acid molecules
#1695Oligomers
#1696RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE
#169717ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof
#1698Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
#1699The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
#1700CHIRALLY ENRICHED OLIGOMERIC COMPOUNDS
#1701Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#1702Methods and compositions for treatment of cholesteryl ester storage disease
#1703OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
#1704Biodegradable lipids for delivery of nucleic acids
#1705Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#1706Compositions and therapeutic methods of microRNA gene delivery
#1707TARGETING KIT WITH SPLICE SWITCHING OLIGONUCLEOTIDES TO INDUCE APOPTOSIS OF MAST CELLS
#1708Splice inhibiting oligonucleotides
#1709SARNA COMPOSITIONS AND METHODS OF USE
#1710OLIGONUCLEOTIDES FOR SNCA MODULATION
#1711Soluble TNF Receptors and Their Use in Treatment of Disease
#1712P-ethoxy nucleic acids for liposomal formulation
#1713METHOD FOR PREVENTING OR TREATING CANCER USING SYT11 INHIBITOR
#1714COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
#1715METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47
#1716OLIGONUCLEOTIDE MEDIATED NO-GO DECAY
#1717MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN
#1718Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome
#1719Methods for using transcription-dependent directed evolution of AAV capsids
#1720Substances for targeting various selected organs or tissues
#1721GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#1722Allele specific modulators of P23H rhodopsin
#1723Synthetic lipid-like materials for brain delivery
#1724Lipid Vesicle for Oral Drug Delivery
#1725Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1726Methods for reducing LRRK2 expression
#1727CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#1728Modified AAV constructs and uses thereof
#17292' FANA MODIFIED FOXP3 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1730Dual-acting siRNA based modulation of C9orf72
#1731Single-stranded RNA-editing oligonucleotides
#1732Use of regulatory T cell-specific surface protein LRIG-1
#1733ANTISENSE NUCLEIC ACIDS
#1734COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLS
#1735Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1736Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1737Compositions and methods for increasing expression of SCN2A
#1738MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING HYPERTROPHIC CARDIOMYOPATHY
#1739MODULATING IMMUNE RESPONSES
#1740MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#1741ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
#1742USE OF AKT INHIBITORS IN OPHTHALMOLOGY
#1743COMPOSITIONS AND METHODS TO CONTROL INSECT PESTS
#1744Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
#1745Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotide
#1746ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#1747SERPINA1 iRNA compositions and methods of use thereof
#1748GENE TARGETS FOR T-CELL-BASED IMMUNOTHERAPY
#1749Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
#1750SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION
#1751METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1752PARN AS A BIOMARKER AND THERAPEUTIC TARGET
#1753AGENT USING HSP47 INHIBITOR TO SUPPRESS METASTASIS
#1754CATIONIC COMPOUNDS FOR DELIVERY OF NUCLEIC ACIDS
#1755Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
#1756Antisense oligomers for treatment of conditions and diseases
#1757MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#1758MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#1759Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#1760METHODS OF TREATING OSMIDROSIS
#1761CELL-PENETRATING PEPTIDES
#1762Cell-penetrating peptides
#1763Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
#1764Selective inhibition of T Follicular Helper cells for treatment of autoimmune disorders
#1765Aerosol-generating device for the inhalation administration of an antisense-molecule-containing composition
#1766HIF 1-alpha antisense oligonucleotides
#1767Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1768MATRIX METALLOPROTEINASE-1 ANTISENSE OLIGONUCLEOTIDES
#1769Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)
#1770Trimeric peptides for antisense delivery
#1771TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING
#1772Methods of treating PACS1 and PACS2 syndromes
#1773Methods for treating hypercholesterolemia
#1774Oligonucleotides targeting frataxin and related methods
#1775Long double-stranded RNA for RNA interference
#1776Compositions for Transfecting Resistant Cell Types
#1777ANTISENSE NUCLEIC ACIDS
#1778METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS
#1779Methods of treating cholangiocarcinoma
#1780Targeting microRNA-101-3p in cancer therapy
#1781Methods of Imaging and Tracking Nucleic Acids in Cells
#1782Small cell lung cancer therapeutic agent containing oligonucleotide
#1783Methods and compositions for sensitization of tumor cells to immune therapy
#1784Methods and compositions for modulating lncRNAs and methods of treatment based on lncRNA expression
#1785Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
#1786MICRORNA-134 BIOMARKER
#1787IL-1 BETA TARGETING SPHERICAL NUCLEIC ACIDS
#1788RNA MOLECULES COMPRISING NON-CANONICAL BASE PAIRS
#1789METHODS AND COMPOSITIONS FOR TARGETING PD-L1
#1790Compounds and methods for the modulation of proteins
#1791Combination therapy with liposomal antisense oligonucleotides
#1792COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES
#1793TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
#1794COMPOSITION COMPRISING ANTISENSE OLIGONUCLEOTIDE AND USE THEREOF FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
#1795ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1
#1796ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#1797CHIMERIC PEPTIDES FOR ANTISENSE DELIVER
#1798METHODS OF TREATING SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS
#1799Exonic splicing enhancers and exonic splicing silencers
#1800METHOD FOR DETERMINING DECREASE IN FUNCTIONS OF HIPPOCAMPUS BY USING CORRELATION BETWEEN MICRO RNA AND NMDA RECEPTOR, METHOD FOR INHIBITING DECREASE IN FUNCTIONS, AND METHOD FOR SCREENING FOR INHIBITORS OF DECREASE IN FUNCTIONS